Specifically, we estimated the relative risk of a new diagnosis of breast cancer among new users of high prolactin increasing antipsychotic drugs (HPDs) compared with new users of non/low prolactin increasing drugs (NPDs). This evidence concerns the gene PRL and breast carcinoma.